Clinical-trials tracker
How much human testing each peptide is actually getting: total registered studies, how many are recruiting, how many are still active, and how many have finished — with the highest phase reached. The metabolic peptides dominate; most research peptides have a handful of trials or none.
Data as of October 26, 2026 ·15,963 trials across 80 compounds
- 15,963trials tracked
- 80compounds in trials
- 1,423recruiting now
- 40notable open studies
Type
Activity
80 compounds shown
| Compound | Total | Recruiting | Active | Completed | Top phase |
|---|---|---|---|---|---|
| L-TyrosineAmino acid | 2,109 | 59 | 32 | 6 | Phase 3 |
| L-PhenylalanineAmino acid | 1,077 | 60 | 21 | 16 | Phase 4 |
| GABAAmino acid | 1,062 | 52 | 6 | 37 | Phase 4 |
| L-SerineAmino acid | 835 | 57 | 14 | 22 | Phase 4 |
| SemaglutidePeptide · Incretin / metabolic | 790 | 58 | 22 | 19 | Phase 4 |
| L-ArginineAmino acid | 789 | 52 | 11 | 33 | Phase 4 |
| L-CysteineAmino acid | 724 | 44 | 12 | 39 | Phase 4 |
| NAC (N-acetylcysteine)Amino acid | 677 | 46 | 12 | 34 | Phase 4 |
| L-DOPA (levodopa)Amino acid | 618 | 44 | 12 | 40 | Phase 4 |
| LiraglutidePeptide · Incretin / metabolic | 515 | 33 | 10 | 42 | Phase 4 |
| L-ValineAmino acid | 443 | 42 | 7 | 33 | Phase 4 |
| ExenatidePeptide · Incretin / metabolic | 379 | 14 | 6 | 55 | Phase 4 |
| CreatineAmino acid | 367 | 54 | 4 | 39 | Phase 4 |
| AlanineAmino acid | 365 | 51 | 21 | 23 | Phase 4 |
| L-LeucineAmino acid | 319 | 55 | 7 | 29 | Phase 3 |
| L-Carnitine / ALCARAmino acid | 312 | 26 | 11 | 46 | Phase 4 |
| TirzepatidePeptide · Incretin / metabolic | 307 | 75 | 14 | 10 | Phase 4 |
| L-GlutamineAmino acid | 291 | 35 | 5 | 37 | Phase 4 |
| GlutathioneAmino acid | 272 | 32 | 13 | 42 | Phase 4 |
| NAD+Peptide · Longevity / mitochondrial | 268 | 57 | 6 | 32 | Phase 4 |
| GlycineAmino acid | 244 | 22 | 11 | 47 | Phase 4 |
| L-LysineAmino acid | 217 | 24 | 11 | 40 | Phase 4 |
| L-MethionineAmino acid | 213 | 26 | 11 | 41 | Phase 4 |
| HomocysteineAmino acid | 188 | 19 | 2 | 53 | Phase 4 |
| L-TryptophanAmino acid | 175 | 30 | 7 | 48 | Phase 4 |
| L-ProlineAmino acid | 174 | 22 | 4 | 44 | Phase 4 |
| L-CitrullineAmino acid | 162 | 21 | 2 | 56 | Phase 4 |
| L-Glutamic acidAmino acid | 159 | 16 | 17 | 37 | Phase 4 |
| TaurineAmino acid | 154 | 21 | 4 | 53 | Phase 4 |
| DulaglutidePeptide · Incretin / metabolic | 143 | 20 | 4 | 62 | Phase 4 |
| L-HistidineAmino acid | 143 | 26 | 7 | 40 | Phase 4 |
| L-OrnithineAmino acid | 125 | 17 | 10 | 51 | Phase 4 |
| L-ThreonineAmino acid | 114 | 20 | 9 | 44 | Phase 4 |
| Aspartic acidAmino acid | 105 | 12 | 7 | 59 | Phase 4 |
| Beta-alanineAmino acid | 87 | 13 | 7 | 54 | Phase 4 |
| Betaine (TMG)Amino acid | 82 | 15 | 3 | 47 | Phase 4 |
| SAMeAmino acid | 71 | 11 | 2 | 44 | Phase 4 |
| Thymosin alpha-1Peptide · Immune / antimicrobial | 66 | 18 | 2 | 24 | Phase 4 |
| L-IsoleucineAmino acid | 60 | 9 | 3 | 31 | Phase 4 |
| L-TheanineAmino acid | 56 | 9 | 0 | 44 | Phase 4 |
| CarnosineAmino acid | 53 | 2 | 1 | 36 | Phase 4 |
| OrforglipronPeptide · Incretin / metabolic | 53 | 13 | 8 | 32 | Phase 4 |
| CagrilintidePeptide · Incretin / metabolic | 44 | 11 | 7 | 24 | Phase 3 |
| CerebrolysinPeptide · Nootropic / mental-health | 43 | 8 | 1 | 19 | Phase 4 |
| MazdutidePeptide · Incretin / metabolic | 43 | 20 | 4 | 18 | Phase 4 |
| RetatrutidePeptide · Incretin / metabolic | 33 | 2 | 10 | 21 | Phase 3 |
| CagriSemaPeptide · Incretin / metabolic | 31 | 6 | 5 | 18 | Phase 3 |
| 5-HTPAmino acid | 29 | 6 | 1 | 18 | Phase 4 |
| LarazotidePeptide · Healing / recovery | 29 | 1 | 2 | 22 | Phase 3 |
| SurvodutidePeptide · Incretin / metabolic | 29 | 8 | 3 | 18 | Phase 3 |
| SermorelinPeptide · GH secretagogues | 27 | 1 | 0 | 21 | Phase 4 |
| SetmelanotidePeptide · Melanocortin | 27 | 3 | 2 | 19 | Phase 4 |
| TesamorelinPeptide · GH secretagogues | 24 | 3 | 0 | 14 | Phase 4 |
| Melanotan I (afamelanotide)Peptide · Melanocortin | 23 | 0 | 1 | 18 | Phase 3 |
| DefensinsPeptide · Immune / antimicrobial | 22 | 1 | 0 | 7 | Phase 4 |
| SS-31 (elamipretide)Peptide · Longevity / mitochondrial | 21 | 2 | 2 | 14 | Phase 4 |
| LL-37Peptide · Immune / antimicrobial | 20 | 2 | 0 | 12 | Phase 3 |
| VIP (vasoactive intestinal peptide)Peptide · Healing / recovery | 20 | 1 | 1 | 13 | Phase 4 |
| Thymosin beta-4Peptide · Healing / recovery | 18 | 3 | 0 | 11 | Phase 3 |
| FollistatinPeptide · GH secretagogues | 15 | 2 | 1 | 11 | Phase 4 |
| AsparagineAmino acid | 14 | 0 | 2 | 10 | Phase 3 |
| TesofensinePeptide · Incretin / metabolic | 13 | 0 | 0 | 11 | Phase 2 |
| Citrulline malateAmino acid | 11 | 0 | 1 | 6 | Phase 2 |
| HydroxyprolineAmino acid | 10 | 0 | 0 | 6 | Phase 4 |
| PT-141 (bremelanotide)Peptide · Melanocortin | 10 | 0 | 1 | 9 | Phase 4 |
| MK-677 (ibutamoren)Peptide · GH secretagogues | 8 | 1 | 0 | 5 | Phase 3 |
| Argireline (acetyl hexapeptide-8)Peptide · Cosmetic / skin | 7 | 0 | 0 | 6 | Phase 3 |
| MOTS-cPeptide · Longevity / mitochondrial | 5 | 3 | 1 | 0 | Phase 2 |
| ARA-290 (cibinetide)Peptide · Healing / recovery | 4 | 0 | 0 | 2 | Phase 2 |
| BPC-157Peptide · Healing / recovery | 4 | 2 | 0 | 1 | Phase 2 |
| HumaninPeptide · Longevity / mitochondrial | 3 | 1 | 0 | 1 | N/A |
| IpamorelinPeptide · GH secretagogues | 3 | 0 | 1 | 2 | Phase 2 |
| GHK-CuPeptide · Cosmetic / skin | 2 | 1 | 0 | 1 | Phase 2 |
| SelankPeptide · Nootropic / mental-health | 2 | 0 | 0 | 1 | N/A |
| CJC-1295Peptide · GH secretagogues | 1 | 0 | 0 | 0 | Phase 2 |
| EpitalonPeptide · Longevity / mitochondrial | 1 | 1 | 0 | 0 | Early Phase 1 |
| Melanotan IIPeptide · Melanocortin | 1 | 1 | 0 | 0 | Phase 2 |
| Palmitoyl tripeptide-1Peptide · Cosmetic / skin | 1 | 0 | 0 | 1 | N/A |
| SelenocysteineAmino acid | 1 | 0 | 0 | 1 | Phase 1 |
| TB-500Peptide · Healing / recovery | 1 | 1 | 0 | 0 | Phase 2 |
What's actively recruiting right now
These studies are open and enrolling as of the date above — the leading edge of peptide research. Retatrutide and the other incretin drugs are running large Phase 3 programs; a few research peptides (BPC-157 among them) have small early-phase trials underway. Each links to its ClinicalTrials.gov record.
| Compound | Phase | Status | Study | Sponsor | Primary completion |
|---|---|---|---|---|---|
| Semaglutide | Phase 4 | Recruiting | NCT07592546Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss | Alain Dagher | Dec 1, 2028 |
| Tirzepatide | Phase 4 | Not yet recruiting | NCT07893457Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity | Mayo Clinic | Oct 26, 2027 |
| Semaglutide | Phase 4 | Recruiting | NCT07058155Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease | The Cleveland Clinic | Feb 1, 2029 |
| Tirzepatide | Phase 4 | Recruiting | NCT07058155Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease | The Cleveland Clinic | Feb 1, 2029 |
| Semaglutide | Phase 4 | Recruiting | NCT06132477Impact GLP-1 Agonists Following Bariatric | University of Missouri-Columbia | Jul 2028 |
| Semaglutide | Phase 4 | Not yet recruiting | NCT06977438GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward | University of Minnesota | Jan 31, 2031 |
| Tirzepatide | Phase 4 | Recruiting | NCT07777575Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide | Technical University of Munich | Aug 31, 2027 |
| GABA | Phase 4 | Not yet recruiting | NCT07288528A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough | McMaster University | Sep 1, 2029 |
| GABA | Phase 4 | Enrolling (invitation) | NCT06997016Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients | Baylor Research Institute | Jun 2027 |
| GABA | Phase 4 | Recruiting | NCT07813026Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users | Viatris Inc. | Jan 31, 2027 |
| L-Cysteine | Phase 4 | Not yet recruiting | NCT07873632Study to Evaluate the Effects of Oral Glyceryl Guiacolate (Guaifenesin, GGE) on Sputum Rheology in Subjects With Mucus Hypersecretion | University of North Carolina, Chapel Hill | Dec 31, 2027 |
| NAC (N-acetylcysteine) | Phase 4 | Not yet recruiting | NCT07873632Study to Evaluate the Effects of Oral Glyceryl Guiacolate (Guaifenesin, GGE) on Sputum Rheology in Subjects With Mucus Hypersecretion | University of North Carolina, Chapel Hill | Dec 31, 2027 |
| Semaglutide | Phase 4 | Not yet recruiting | NCT07872904FutureShape Family | Signe Torekov | May 31, 2030 |
| L-Proline | Phase 4 | Enrolling (invitation) | NCT07547878Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) | Baylor Research Institute | Mar 31, 2029 |
| L-Valine | Phase 4 | Enrolling (invitation) | NCT07547878Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) | Baylor Research Institute | Mar 31, 2029 |
| Mazdutide | Phase 4 | Recruiting | NCT07657676Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity | China National Center for Cardiovascular Diseases | Dec 31, 2027 |
| Semaglutide | Phase 4 | Enrolling (invitation) | NCT07547878Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) | Baylor Research Institute | Mar 31, 2029 |
| Semaglutide | Phase 4 | Recruiting | NCT07870538A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum | Universitaire Ziekenhuizen KU Leuven | Dec 2028 |
| GABA | Phase 4 | Enrolling (invitation) | NCT07750639Reducing Opioid Use After Upper Extremity Surgery: Testing Lower Prescriptions and Pill Quantity | AdventHealth | Nov 30, 2027 |
| GABA | Phase 4 | Not yet recruiting | NCT07859839Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD | Post Graduate Institute of Medical Education and Research, Chandigarh | Jun 30, 2027 |
| GABA | Phase 4 | Recruiting | NCT07840183Epidural Analgesia Versus Opioid-sparing Analgesia for Open Ventral Hernia Repair With Transversus Abdominis Release | Northwestern University | Sep 2027 |
| L-Carnitine / ALCAR | Phase 4 | Not yet recruiting | NCT07862725Comparative Efficacy of Antioxidants Alone Versus Combined Therapy With SERMs or FSH in Normogonadotropic Idiopathic OAT Patients: A Randomized Controlled Trial | Hamad Medical Corporation | Oct 15, 2027 |
| Tirzepatide | Phase 4 | Recruiting | NCT07218445The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity | Mayo Clinic | Sep 18, 2027 |
| GABA | Phase 4 | Recruiting | NCT06379425Impact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries | Northwell Health | Jan 1, 2027 |
| NAD+ | Phase 4 | Not yet recruiting | NCT07832084Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s | Jing Luo | Apr 30, 2027 |
| Semaglutide | Phase 4 | Not yet recruiting | NCT07832084Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s | Jing Luo | Apr 30, 2027 |
| Semaglutide | Phase 4 | Recruiting | NCT06706284Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes | Marzieh Salehi | Sep 1, 2028 |
| Semaglutide | Phase 4 | Not yet recruiting | NCT07859137Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher | General Committee of Teaching Hospitals and Institutes, Egypt | Nov 2028 |
| Semaglutide | Phase 4 | Not yet recruiting | NCT07859176Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery | General Committee of Teaching Hospitals and Institutes, Egypt | Apr 2028 |
| Semaglutide | Phase 4 | Not yet recruiting | NCT07859163Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain | General Committee of Teaching Hospitals and Institutes, Egypt | Apr 2029 |
| Semaglutide | Phase 4 | Not yet recruiting | NCT07858331Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access | Kristin Clemens | Jan 1, 2029 |
| Semaglutide | Phase 4 | Not yet recruiting | NCT07859189Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery | General Committee of Teaching Hospitals and Institutes, Egypt | Oct 2028 |
| Semaglutide | Phase 4 | Not yet recruiting | NCT07859150Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE) | General Committee of Teaching Hospitals and Institutes, Egypt | Apr 2029 |
| Tirzepatide | Phase 4 | Not yet recruiting | NCT07832084Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s | Jing Luo | Apr 30, 2027 |
| L-Serine | Phase 4 | Recruiting | NCT06571149Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake | Insel Gruppe AG, University Hospital Bern | Jan 31, 2029 |
| L-DOPA (levodopa) | Phase 4 | Recruiting | NCT07839793A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients | Navamedic AB | Mar 31, 2027 |
| L-Carnitine / ALCAR | Phase 4 | Recruiting | NCT07642076Evaluation of the Clinical Impact of Adjunctive L-carnitine Therapy in Critically Ill Hepatic Patients Admitted to Intensive Care Unit | Beni-Suef University | Dec 2026 |
| Mazdutide | Phase 4 | Recruiting | NCT07718126Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) | West China Hospital | Feb 28, 2029 |
| L-Serine | Phase 4 | Not yet recruiting | NCT07816978Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism | Sahlgrenska University Hospital | Jan 31, 2030 |
| Mazdutide | Phase 4 | Not yet recruiting | NCT07824895Mazdutide for Weight Management and Gout in Adults With Obesity | Hongwei Jiang | Dec 31, 2027 |
How this tracker is built
Counts come from the ClinicalTrials.gov API (v2), queried by intervention name for each compound. Total is every registered study; recruitingcounts those actively enrolling; active means underway but no longer recruiting; completed means the study has finished. A compound with zero trials simply isn't listed here — an honest gap, not a hidden row. The table refreshes whenever the site rebuilds, so the "as of" date is the real freshness.